Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)

Bays, Harold; Braeckman, René; Ballantyne, Christie M.; Kastelein, John J.P.; Otvos, James D.; Stirtan, William G.; Soni, Paresh N.

doi:10.1016/j.jacl.2012.07.001

Cited by 76 publications

(55 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the authors, omega-3 supplementation and statins can negatively interact with each other, leading to a reduction in the final action on dyslipidaemia. Icosapent ethyl can potentially reduce the need for statins, as it has been demonstrated to actively reduce both triacylglycerols and total LDL particle (IDL, small LDL, large LDL) concentrations (Bays et al 2012). Nevertheless, further studies are needed to confirm these findings.…”

Section: Nutraceuticals Versus Lipid Lowering Drugs In Dyslipidaemia mentioning

confidence: 99%

“…Nevertheless, the use of icosapent ethyl, a high-purity prescription form of eicosapentaenoic acid ethyl ester appears to overcome the limitations of normal fish oil and omega-3 fatty acids with LDL particles. Bays et al (2012) demonstrated that, in fact, a reduced total LDL particle concentration (IDL particles, small LDL particles, and large LDL particles) of approximately 16.3% (p = 0.0006), whereas the small LDL particle concentrations were reduced by approximately 25.6% (p < 0.0001) and 12.8% (p = 0.0274) when administering 4 and 2 g/day of icosapent ethyl, respectively.…”

mentioning

confidence: 95%

See 1 more Smart Citation

Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

Scicchitano

Cameli

Maiello³

et al. 2014

Journal of Functional Foods

320

236

View full text Add to dashboard Cite

Section: Nutraceuticals Versus Lipid Lowering Drugs In Dyslipidaemia mentioning

confidence: 99%

mentioning

confidence: 95%

Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

Scicchitano

Cameli

Maiello³

et al. 2014

Journal of Functional Foods

320

236

View full text Add to dashboard Cite

“…The MARINE study (Multi-center, pIAcebo-controlled, Randomized, double-blINd, 12-week study with an openlabel Extension) investigated the efficacy and safety of an omega-3 fatty acid (containing ≥96 % pure icosapent ethyl) in patients with very high triglyceride levels (≥500 mg/dL) [73]. The 2 g/day dose of the omega-3 agent increased HDL-C by 3.3 % with no change in HDL-P levels.…”

Section: Therapeutic Interventionsmentioning

confidence: 99%

Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy

Rosenson

Davidson

et al. 2015

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

The inverse relationship between high-density lipoprotein cholesterol (HDL-C) concentrations and coronary heart disease risk is well established. As a result, in recent years there have been significant resources focused on identifying therapies that raise HDL-C and ultimately reduce cardiovascular events. Unfortunately, a number of trials aimed at increasing HDL-C have failed to show improved outcomes, and hence, have cast doubt on the importance of HDL-C as a therapeutic target. HDL-C, however, is only one measure of HDL. HDL levels can also been estimated by quantifying apolipoprotein A-I (apoA-I) levels using enzyme immunoassay or by measuring HDL particle number (HDL-P) using nuclear magnetic resonance spectroscopy (NMR) or ion mobility. While these surrogate measures are correlated, they are not comparable. Lipoprotein-altering therapies have been shown to have different effects on HDL-C, apoA-I and HDL-P and several studies have demonstrated that HDL-P is a stronger predictor of coronary heart disease risk than HDL-C and/or apoA-I. This paper will review available evidence supporting the use of HDL-P as the biomarker of choice to assess the contribution of HDL to cardiovascular risk and as the primary goal of HDL-raising therapies.

show abstract

“…However, the 2 g/day did not have the statistically significant reductions on these lipoprotein parameters [34].…”

Section: Effects Of Eicosapentaenoic Acid and Docosahexaenoic Acid Onmentioning

confidence: 73%

“…The multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension study studied the triglyceridelowering effect of icosapent ethyl, which is an v-3 fatty acid with 96% pure ethyl ester of EPA [25,33]. The study specifically looked at the effect of icosapent ethyl in severe HTG patients who had triglyceride levels at least 500 mg/dl and the impact on other lipoproteins, which included LDL, VLDL, HDL, non-HDL, total cholesterol, and lipoproteinassociated phospholipase A3 [34]. The study included 229 patients (24.9% with triglyceride !…”

Section: Effects Of Eicosapentaenoic Acid and Docosahexaenoic Acid Onmentioning

confidence: 99%

Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia

Patel

Budoff

2016

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of reviewThe treatment of hypertriglyceridemia (HTG) with v-3 fatty acid preparations adds a novel therapy to reduce cardiovascular disease. This review examines the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid on lipoproteins and the cardioprotective effects in HTG. Recent findingsThe evidence that v-3 fatty acid therapy at prescription strength is effective and safe at lowering triglyceride levels is growing. Although EPA/docosahexaenoic acid formulations did lower triglyceride levels, an increase in low-density lipoproteins was observed and outcome data were mixed. More recent trials have shown that decreased levels of low-density lipoprotein can be achieved with EPA preparations. Although the cardiovascular outcomes data are not fully available, meta-analysis of available data reports protection against vascular disease. SummaryThe addition of v-3 fatty acid treatment should be considered in patients with severe HTG as well as high-risk patients for atherosclerotic disease. Emerging data are supportive, but long-term outcome studies are still underway.

show abstract

Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)

Cited by 76 publications

References 30 publications

Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

Nutraceuticals and dyslipidaemia: Beyond the common therapeutics

Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy

Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia

Contact Info

Product

Resources

About